title: Baseline magnetic resonance imaging parameters and stroke outcome in patients treated by intravenous tissue plasminogen activator.
abstract: OBJECTIVE
  We designed a prospective sequential pretreatment and posttreatment MRI study to assess the relation between neuroimaging parameters and clinical outcome in patients treated with intravenous recombinant tissue-type plasminogen activator (rtPA).
  
  
  METHODS
  Patients with symptoms of acute hemispheric ischemic stroke were recruited. The National Institutes of Health Stroke Scale (NIHSS) score was assessed at baseline and at days 1, 7, and 60, and the modified Rankin scale (mRS) at day 60, by which outcome was classified in terms of independence (mRS score 0, 1, or 2) or severe disability or death (mRS score 3 through 6), was assigned. Multimodal stroke MRI was performed at presentation and repeated at day 1. MRI procedures included magnetic resonance angiography, T2* gradient-echo sequence, echoplanar imaging, and isotropic diffusion- (DWI) and perfusion-weighted (PWI) imaging. Patients were treated with intravenous rtPA after MRI completion.
  
  
  RESULTS
  Twenty-nine patients (16 men and 13 women; mean+/-SD age, 65+/-14 years) underwent MRI; the mean time from symptom onset to treatment was 255+/-62 minutes. Twenty-six patients had a vessel occlusion, and 15 patients experienced a partial (Thrombolysis in Myocardial Infarction [TIMI]-2) or total (TIMI-3) recanalization at day 1, whereas 11 patients had a persistent occlusion. Mean NIHSS scores at day 60 were 5.7+/-5.4 if recanalization had occurred and 14+/-2 in cases of persistent occlusion. According to the mRS, 13 patients were independent (mRS 0 through 2), whereas severe disability or death (mRS 3 through 6) was observed in 15 patients. A better outcome was observed when recanalization was achieved (r=-0.68, P=0.0002). PWI volume and time to peak (TTP) within the DWI lesion assessed before therapy were correlated with day-60 NIHSS score (PWI volume: r=0.51, P=0.006, TTP: r=0.35, P=0.07). The day-0 DWI abnormality volume was well correlated with day-60 NIHSS score (r=0.58, P=0.001). Multiple regression linear analysis showed that 2 factors mainly influenced clinical outcome: (1) recanalization, with a high correlation with NIHSS score at day 60 (P=0.0001) and (2) day-0 DWI lesion volume, which is closely associated with day-60 NIHSS score (P=0.03).
  
  
  CONCLUSIONS
  Baseline DWI volume and recanalization are the main factors influencing clinical outcome after rtPA for ischemic stroke.
authors.affiliation: Cerebrovascular Disease Center, Hôpital Neurologique et Neurochirurgical Pierre Wertheimer, Lyon, France. norbert.nighoghossian@chu-lyon.fr
authors.forename: N
authors.initials: N
authors.lastname: Nighoghossian
authors.forename: M
authors.initials: M
authors.lastname: Hermier
authors.forename: P
authors.initials: P
authors.lastname: Adeleine
authors.forename: L
authors.initials: L
authors.lastname: Derex
authors.forename: J F
authors.initials: JF
authors.lastname: Dugor
authors.forename: F
authors.initials: F
authors.lastname: Philippeau
authors.forename: H
authors.initials: H
authors.lastname: Ylmaz
authors.forename: J
authors.initials: J
authors.lastname: Honnorat
authors.forename: P
authors.initials: P
authors.lastname: Dardel
authors.forename: Y
authors.initials: Y
authors.lastname: Berthezène
authors.forename: J C
authors.initials: JC
authors.lastname: Froment
authors.forename: P
authors.initials: P
authors.lastname: Trouillas
mesh_terms: D000208:Acute Disease; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D004058:Diffusion; D018450:Disease Progression; D017352:Echo-Planar Imaging; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D016014:Linear Models; D018810:Magnetic Resonance Angiography; D008279:Magnetic Resonance Imaging / Q000379:methods; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011994:Recombinant Proteins / Q000008:administration & dosage; D012720:Severity of Illness Index; D020521:Stroke / Q000175:diagnosis* / Q000188:drug therapy*; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage*; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
chemical_list: D011994:Recombinant Proteins; D010959:Tissue Plasminogen Activator